J. Goldman & Co’s Stoke Therapeutics STOK Stock Holding History

J. Goldman & Co’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,500	Closed	-$166K	–	617
2024 Q3	$166K	Buy	+13,500	New	+$191K	﹤0.01%	422

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

J. Goldman & Co's STOK Position: Q1 2026 in Review

J. Goldman & Co sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 6,827 shares — an estimated $217K sold.

J. Goldman & Co first reported a position in STOK in Q4 2025 and held it in 1 quarter. The position peaked at $217K in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

J. Goldman & Co reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 6,827 Stoke Therapeutics shares in Q1 2026, an estimated $217K.
J. Goldman & Co first reported a position in Stoke Therapeutics in Q4 2025 and held it in 1 quarter.
J. Goldman & Co's Stoke Therapeutics position peaked at $217K in Q4 2025.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.